scholarly journals Compounds From the Root of Pueraria peduncularis (Grah. ex Benth.) Benth. and Their Antitumor Effects

2019 ◽  
Vol 14 (11) ◽  
pp. 1934578X1988252
Author(s):  
Huabao Chen ◽  
Yong Qian ◽  
Xiaomin Zhao ◽  
Tianxing Lv ◽  
Bin Wang ◽  
...  

Pueraria peduncularis belongs to the genus Pueraria DC., and has a wide range of medicinal and agricultural values. Previous studies have shown that methanol extracts of P. peduncularis had broad range bioactivities against different pests such as insects, phytopathogens, and snails; however, the specific studies with regard to active compounds against these pests have not been reported. In the current study, we systematically assessed the effects of P. peduncularis root extract against cancer cells, and we also isolated, purified, and analyzed the active ingredients of 8 different compounds from the root of P. peduncularis. To the best of our knowledge, coumestrol (compound 1), lupinalbin A (compound 2), wighteone (compound 6), and erythrinin C (compound 4) were the first isolated from the P. peduncularis root in our study. The extract of the P. peduncularis root had a significantly strong cytotoxic activity on the lung adenocarcinoma cell line A549 (31.0%) and breast cancer cell line MCF-7 (33.0%), respectively. Lupinalbin A (compound 2), erythrinin C (compound 4), pedunsaponin A (compound 7), and pedunsaponin C (compound 8) had more than 40% inhibitory effects on the lung adenocarcinoma line A549. Whereas erythrinin C (compound 4) and pedunsaponin C inhibited more than 47% breast cancer cell lines MCF-7. These results indicate that P. peduncularis is rich in anticancer substances that laid the foundation for a further understanding of P. peduncularis and need to be further explored for other diseases.

2019 ◽  
Vol 2019 ◽  
pp. 1-13 ◽  
Author(s):  
Thandi Mqoco ◽  
André Stander ◽  
Anna-Mart Engelbrecht ◽  
Anna M Joubert

Current chemotherapeutic agents have many side effects and are toxic to normal cells, providing impetus to identify agents that can effectively eliminate tumorigenic cells without damaging healthy cells. The aim of this study was to examine whether combining a novel BRD4 inhibitor, ITH-47, with the antimitotic estradiol analogue, ESE-15-ol, would have a synergistic effect on inhibiting the growth of two different breast cancer cell lines in vitro. Our docking and molecular dynamics studies showed that compared to JQ1, ITH-47 showed a similar binding mode with hydrogen bonds forming between the ligand nitrogens of the pyrazole, ASN99, and water of the BRD4 protein. Data from cell growth studies revealed that the GI50 of ITH-47 and ESE-15-ol after 48 hours of exposure was determined to be 15 μM and 70 nM, respectively, in metastatic MDA-MB-231 breast cancer cells. In tumorigenic MCF-7 breast cancer cells, the GI50 of ITH-47 and ESE-15-ol was 75 μM and 60 nM, respectively, after 48 hours of exposure. Furthermore, the combination of 7.5 μM and 14 nM of ITH-47 and ESE-15-ol, respectively, resulted in 50% growth inhibition of MDA-MB-231 cells resulting in a synergistic combination index (CI) of 0.7. Flow cytometry studies revealed that, compared to the control, combination-treated MDA-MB-231 cells had significantly more cells present in the sub-G1 phase and the combination treatment induced apoptosis in the MDA-MB-231 cells. Compared to vehicle-treated cells, the combination-treated cells showed decreased levels of the BRD4, as well as c-Myc protein after 48 hours of exposure. In combination, the selective BRD4 inhibitor, ITH-47, and ESE-15-ol synergistically inhibited the growth of MDA-MB-231 breast cancer cells, but not of the MCF-7 cell line. This study provides evidence that resistance to BRD4 inhibitors may be overcome by combining inhibitors with other compounds, which may have treatment potential for hormone-independent breast cancers.


2016 ◽  
Vol 2 (1) ◽  
pp. 34
Author(s):  
Tarwadi . ◽  
Churiyah . ◽  
Olivia Bunga Pongtuluran ◽  
Fifit Juniarti ◽  
Fery Azis Wijaya

Sambiloto (Andrographis paniculata) banyak digunakan untuk mengobati berbagai penyakit di Indonesia dan negara-negara Asia lainnya. Dalam studi ini, ekstrak metanol dan etanol sambiloto yang diperoleh dari B2PTO Tawangmangu telah diuji terhadap sel lini kanker payudara T47D dan MCF-7 dan sel lini normal fibroblast HFL-1 menggunakan reaksi enzimatik 3-(4,5-dimethylthiazoyl-2-yl) 2,5-diphenyltetrazoliumbromide (MTT). Uji in vitro terhadap sel lini normal fibroblast HFL-1 menunjukkan bahwa 50 ppm ekstrak metanol sambiloto tidak menghambat pertumbuhan sel. Tetapi, ekstrak metanol dan etanolnya menghasilkan IC50 yang relatif rendah pada sel lini kanker payudara, yaitu 111 ppm dan 122 ppm pada sel lini MCF-7 dan 70 ppm dan 197 ppm pada sel lini T47D. Selain itu, campuran ekstrak sambiloto yang mengandung 25% ekstrak Thyponium divaricatum dan Anredera cordifolia memberikan daya hambat pertumbuhan pada sel kanker payudara MCF-7 yang lebih besar, dengan nilai IC50 masing-masing adalah 68 ppm dan 34 ppm. Kesimpulannya, total ekstrak metanol atau etanol sambiloto yang diperoleh dari Tawangmangu memiliki potensi sebagai sumber senyawa anti-kanker serta perlu kajian lebih lanjut.Kata kunci: Ekstrak Andrographis paniculata, MTT, sel lini normal, sel lini kanker, aktivitas anti kanker ABSTRACTSambiloto (Andrographis paniculata) is widely used as medicine to treat various diseases in Indonesia and other Asian countries. In this study, methanolic and ethanolic extracts of sambiloto collected from B2PTO Tawangmangu have been tested againts breast cancer cell lines of T47D and MCF-7 and normal fibroblast cell line of HFL-1 using enzymatic reaction of 3-(4,5-dimethylthiazoyl-2-yl) 2,5-diphenyltetrazoliumbromide (MTT). In vitro assay performed on normal fibroblast of HFL-1 cell line showed that 50 ppm of methanolic extract of sambiloto did not inhibit cell growth. However, methanolic and ethanolic extracts of sambiloto gave relatively low of IC50 on breast cancer cell lines which were 111 ppm and 122 ppm on the MCF-7 cell lines and 70 ppm and 197 ppm on the T47D cell lines, respectively. In addition, the mixture of sambiloto extract containing 25% of Thyponium divaricatum and Anredera cordifolia extracts confered greater growth inhibition on breast cancer cell line of MCF-7, where IC50 values were 68 ppm and 34 ppm, respectively. In conclusion, the total methanolic or ethanolic extract of sambiloto collected from Tawangmangu has potency as a source of anti-cancer compounds and needs further study.Key words: Andrographis paniculata extract, MTT, normal cell line, cancer cell lines, anti-cancer activity


2009 ◽  
Vol 2 (3) ◽  
pp. 160-165 ◽  
Author(s):  
Menka Khoobchandani ◽  
B. K. Ojeswi ◽  
Bhavna Sharma ◽  
Man Mohan Srivastava

The present study is aimed to investigate the effects ofChenopodium album(leaves) on the growth of estrogen dependent (MCF-7) and estrogen independent (MDA-MB-468) human breast cancer cell lines. The different solvent extracts (petroleum ether, ethyl acetate and methanol) were assessed for their cytotoxicity using TBE (Trypan blue exclusion) and MTT [3-(4, 5-dimethyl thiazol-2-yl)-2, 5-diphenyl tetrazolium] bioassay. These cells were cultured in MEM (minimum essential medium) medium and incubated with the dilution series of extracts (10–100 mg/ml) in CO2incubator at 37°C for 24 h. Among the various extracts studied for two cell lines, methanolic extract ofC. album(leaves) exhibited maximum antibreast cancer activity having IC50(the concentration of an individual compound leading to 50% inhibition) value 27.31 mg/ml against MCF-7 cell line. Significant percent inhibition (94.06%) in the MeOH extract ofC. album(leaves) at 48 h of exposure and concentration 100 mg/ml (p < 0.05) against MCF-7 breast cancer cell line, indicates the presence of some structural moiety responsible for this observed antiproliferative effect. In vivo study and structural elucidation of its bioactive principle are in progress. Our findings highlight the potential of this plant for its possible clinical use to counteract malignancy development as antibreast cancer bioagent.


2013 ◽  
Vol 13 (2) ◽  
pp. 130-135 ◽  
Author(s):  
Theera Srisawat ◽  
Parinuch Chumkaew ◽  
Warapond Maichum ◽  
Yaowapa Sukpondma ◽  
Potchanapond Graidist ◽  
...  

2022 ◽  
Vol 2022 ◽  
pp. 1-10
Author(s):  
Pan Tang ◽  
Yanyan Shen ◽  
Jihui Yang ◽  
Nan Wen ◽  
Ying Liu ◽  
...  

Breast cancer is the most common female cancer in the world. Breast cancer patients are currently treated with a combination of surgery, chemotherapy, radiotherapy, and targeted therapy, but the 5-year overall survival rate is still low. Therefore, we plan to explore the potential interaction mechanism between miR-622 and EYA1 in the breast cancer cells and their effect on proliferation, migration, and invasion of breast cancer, to lay a foundation for the gene therapy of breast cancer and improve the therapeutic effect. This study found that miR-622 was highly expressed in breast cancer cell lines, while EYA1 was poorly. In MCF-7 cell line, miR-622 had the highest expression level, while EYA1 had the lowest. Besides, the bioinformatics analysis showed that EYA1 possesses putative miR-622 binding sites within its 3 ′ UTR. The increased miR-622 significantly enhanced the proliferation, migration, and invasion of MCF-7 cell line and inhibited luciferase reporter activity in the 3 ′ UTR of EYA1-WT. When upregulating the expression of miR-622, the mRNA and protein expression levels of EYA1 were significantly decreased. We also found that the silencing of EYA1 promoted the proliferation, migration, and invasion of breast cancer MCF-7 cell line. These results indicate that miRNA-622 plays a tumor-promoting role in breast cancer through targeted negative regulation of EYA1, suggesting that miRNA-622 may become a potential target for breast cancer treatment.


2018 ◽  
Vol 8 (3) ◽  
pp. 159 ◽  
Author(s):  
Meghan Fragis ◽  
Abdulmonem I. Murayyan ◽  
Suresh Neethirajan

Background: Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer deaths among Canadian women. Cancer management through changes in lifestyle, such as increased intake of foods rich in dietary flavonoids, have been shown to decrease the risk associated with breast, liver, colorectal, and upper-digestive cancers in epidemiologic studies. Onions are high in flavonoid content and one of the most common vegetables. Additionally, onions are used in most Canadian cuisines.Methods: We investigated the effect of five prominent Ontario grown onion (Stanley, Ruby Ring, LaSalle, Fortress, and Safrane) extracts on two subtypes of breast cancer cell lines: a triple negative breast cancer line MDA-MB-231 and an ER+ breast cancer line MCF-7.Results: These onion extracts elicited strong anti-proliferative, anti-migratory, and cytotoxic activities on both the cancer cell lines. Flavonoids present in these onion extracts induced apoptosis, cell cycle arrest in the G2/M phase, and a reduction in mitochondrial membrane potential at dose-dependent concentrations. Onion extracts were more effective against MDA-MB-231 compared to the MCF-7 cell line. Conclusion: In this study, we investigated the extracts synthesized from Ontario-grown onion varieties in inducing anti-migratory, cytostatic, and cytotoxic activities in two sub-types of human breast cancer cell lines. Anti-tumor activity of these extracts depends upon the varietal and can be formulated into nutraceuticals and functional foods for the wellbeing of cancer patients. Overall, the results suggest that onion extracts are a good source of flavonoids with anti-cancerous properties.Keywords: onion extracts; flavonoids; anti-proliferative; breast cancer; cytotoxic activity


2017 ◽  
Vol 63 (1) ◽  
pp. 141-145
Author(s):  
Yuliya Khochenkova ◽  
Eliso Solomko ◽  
Oksana Ryabaya ◽  
Yevgeniya Stepanova ◽  
Dmitriy Khochenkov

The discovery for effective combinations of anticancer drugs for treatment for breast cancer is the actual problem in the experimental chemotherapy. In this paper we conducted a study of antitumor effect of the combination of sunitinib and bortezomib against MDA-MB-231 and SKBR-3 breast cancer cell lines in vitro. We found that bortezomib in non-toxic concentrations can potentiate the antitumor activity of sunitinib. MDA-MB-231 cell line has showed great sensitivity to the combination of bortezomib and sunitinib in vitro. Bortezomib and sunitinib caused reduced expression of receptor tyrosine kinases VEGFR1, VEGFR2, PDGFRa, PDGFRß and c-Kit on HER2- and HER2+ breast cancer cell lines


Sign in / Sign up

Export Citation Format

Share Document